1-(4-N,N-dimethylamino-phenyl)-2-(pyridin-4-yl)-1H-imidazo[4,5-b]pyrazine | 1350629-11-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-N,N-dimethylamino-phenyl)-2-(pyridin-4-yl)-1H-imidazo[4,5-b]pyrazine
• 英文别名: N,N-dimethyl-4-(2-pyridin-4-ylimidazo[4,5-b]pyrazin-3-yl)aniline
• CAS: 1350629-11-6
• 化学式: C₁₈H₁₆N₆
• 分子量: 316.365
• InChiKey: QUVDZXLPWUMGOO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  59.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N,N-二甲基-对苯二胺 在 palladium diacetate 、 sodium hydride 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium t-butanolate 作用下， 以 二甲基亚砜 、 甲苯 为溶剂， 反应 24.0h， 生成 1-(4-N,N-dimethylamino-phenyl)-2-(pyridin-4-yl)-1H-imidazo[4,5-b]pyrazine
  参考文献：
  名称：

  可调荧光发射的1,2-二取代（杂）芳基稠合咪唑的区域专一性合成

  摘要：

  建立了钯催化的两倍或四倍胺化反应，该反应可以区域特异性合成1,2-二取代（杂）芳基稠合的咪唑的多样性导向文库，并为发现具有可调荧光发射的荧光支架提供了出色的工具。这些荧光团已被用作活细胞成像的荧光探针。

  DOI：

  10.1021/ol202807d

文献信息

• COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY
  申请人：Annapurna Bio, Inc.

  公开号：US20220125787A1

  公开（公告）日：2022-04-28

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS DESTINÉS AU TRAITEMENT D'ÉTATS PATHOLOGIQUES ASSOCIÉS À UNE ACTIVITÉ DU RÉCEPTEUR DE L'APJ
  申请人：ANNAPURNA BIO INC

  公开号：WO2020073011A1

  公开（公告）日：2020-04-09

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.
• Regiospecific Synthesis of 1,2-Disubstituted (Hetero)aryl Fused Imidazoles with Tunable Fluorescent Emission
  作者：Dongbing Zhao、Junyi Hu、Ningjie Wu、Xiaolei Huang、Xurong Qin、Jingbo Lan、Jingsong You

  DOI：10.1021/ol202807d

  日期：2011.12.16

  A palladium-catalyzed two or fourfold amination was established that allows regiospecific synthesis of a diversity-oriented library of 1,2-disubstituted (hetero)aryl fused imidazoles, and provides an exceptional tool for the discovery of fluorescent scaffolds with tunable fluorescence emission. These fluorophores have been applied as fluorescent probes for live cell imaging.

  建立了钯催化的两倍或四倍胺化反应，该反应可以区域特异性合成1,2-二取代（杂）芳基稠合的咪唑的多样性导向文库，并为发现具有可调荧光发射的荧光支架提供了出色的工具。这些荧光团已被用作活细胞成像的荧光探针。